Jiangxi Cancer Hospital
Nanchang, Jiangxi, 330029, China
NCT Number: NCT06762470
In our previous retrospective study, we identified circulating immune cell counts and the CD4/CD8 ratio as significant prognostic markers in nasopharyngeal carcinoma. Building on these findings, this study aims to conduct a multi-center prospective observational study to evaluate the prognostic value of the circulating lymphocyte CD4/CD8 ratio in nasopharyngeal carcinoma patients prior to treatment.
This study is active but is not currently recruiting participants.
Notify Me18 year–70 year
All sexes
Observational
Nanchang, Jiangxi, 330029, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 3 Years
The time from the first diagnosis of nasopharyngeal carcinoma to the first observation of disease progression or death from any cause
Time frame: 3 Years
The time from the first diagnosis of nasopharyngeal carcinoma to the occurrence of death from any cause
Time frame: 3 years
Distant metastasis-free survival (DMFS) was defined as the time from diagnosis to the occurrence of distant metastasis or the date of censoring, whichever came first.
Time frame: 3 Years
Locoregional recurrence-free survival (LRRFS) was defined as the time from diagnosis to the occurrence of locoregional recurrence or the date of censoring, whichever came first.
Jiangxi Provincial Cancer Hospital
Other
Prognostic Value of Pretreatment Peripheral Circulating Lymphocyte CD4/CD8 Ratio in Patients with Non-metastatic Nasopharyngeal Carcinoma: a Multi-center Prospective Observational Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05813626
Carcinoma, Head and Neck Neoplasms
Hangzhou, Zhejiang, China
View Trial DetailsNCT05063552
Carcinoma, Carcinoma, Squamous Cell
Little Rock, Arkansas, United States
View Trial DetailsNCT02135042
Carcinoma, DNA Virus Infections
Birmingham, Alabama, United States
View Trial DetailsNCT04925544
Carcinoma, DNA Virus Infections
Stanford, California, United States
View Trial Details